On June 17, 2022, the U.S. FDA authorized the Moderna pediatric vaccine for children 12 to 17 years old under an Emergency Use Authorization (EUA), meaning the vaccine was proven safe and effective for this age group. The vaccine is the same dosage and formula as the vaccine approved for adults 18 and older. Each dose is 100 mcg. In the FDA analysis, the immune response of the children to the vaccine was comparable to the immune response of the adults.
This vaccine is a two-dose series, and the doses should be administered four to eight weeks apart. An 8-week interval between the first and second doses may be best for some people age 12 and older, especially for males ages 12 to 39. Learn more here or talk with your healthcare provider.
See the U.S. FDA fact sheet for more information.